Patients with pure heterozygous familial hypercholesterolaemia usually develop severe cardiovascular disease in childhood and die in their 20s and 30s.
Patients with untreated heterozygous familial hypercholesterolaemia also have a significantly earlier onset of cardiovascular disease than the general population, and most patients also die from cardiovascular disease, although no average life expectancy has been reported.